A Study of Mirikizumab (LY3074828) in Healthy Participants

Inclusion Criteria: * Are overtly healthy males or females, as determined by medical history and physical examination. * Are first generation Japanese or are Caucasian. * Have a body mass index (BMI) of 18.0 kilograms per square meter (kg/m2) to 32.0 kg/m2, inclusive, at screening. * Have a body weight of 40.0 kg or higher for Cohorts 1, 2, 3 and 4, and 48.0 kg or higher for Cohort 5 and 6. Exclusion Criteria: * Have had symptomatic herpes zoster within 3 months of screening. * Show evidence of active or latent tuberculosis (TB), as documented by medical history and examination, chest x-rays (posterior anterior and lateral), and TB testing. * Have received live vaccine(s) within 1 month of screening or intend to during the study. * Are immunocompromised. * Have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing.